ELI LILLY & Co

ELI LILLY reported strong second-quarter results with revenue increasing by 48% to $23.0 billion and net income rising by 25% to $7.1 billion. Diluted EPS grew by 26% to $7.94. The company continued its aggressive acquisition strategy, completing several business combinations and asset acquisitions, including Kelonia, Centessa, and Ventyx, and issuing $9.0 billion in long-term debt to support these activities.

Eli Lilly reported strong second-quarter 2026 financial results, with revenue increasing 48% to $23.0 billion and non-GAAP EPS rising 33% to $8.38. The company raised its full-year 2026 revenue guidance to a range of $85.0 billion to $87.0 billion, reflecting continued strong performance. Key growth drivers included Mounjaro and Zepbound, alongside significant pipeline progress for retatrutide and strategic business development activities, including multiple acquisitions and manufacturing expansion.

Eli Lilly and Company completed a debt offering totaling $9 billion in aggregate principal amount, consisting of both floating and fixed-rate notes across various maturities. The net proceeds from the offering were approximately $8.94 billion, after deducting underwriting discounts. A portion of these notes are subject to a special mandatory redemption at 101% of principal if the Centessa Acquisition is not consummated by a specified date.

Eli Lilly & Co (LLY) reported robust first-quarter 2026 results, with revenue surging 55.5% to $19.8 billion and net income increasing 168.1% to $7.4 billion. Diluted EPS rose 170% to $8.26. Growth was primarily driven by strong sales of Mounjaro and Zepbound. The company also completed the acquisition of Ventyx Biosciences for $1.1 billion and noted an unfavorable development in the Emgality patent litigation.

Eli Lilly and Company reported strong first-quarter 2026 financial results, with revenue increasing 56% to $19.8 billion and reported EPS rising 170% to $8.26. The company raised its full-year 2026 revenue guidance to a range of $82.0 billion to $85.0 billion and non-GAAP EPS guidance to $35.50 to $37.00. Key drivers included significant volume growth from new medicines like Mounjaro and Zepbound, alongside the U.S. FDA approval of Foundayo for obesity. Lilly also highlighted pipeline progress and strategic business development with four acquisitions.

Eli Lilly reported strong third-quarter 2025 financial results, with revenue increasing 54% year-over-year to $17.6 billion, driven by volume growth from Mounjaro and Zepbound. The company also raised its full-year 2025 revenue guidance to $63.0-$63.5 billion and EPS guidance to $21.80-$22.50 (reported) and $23.00-$23.70 (non-GAAP), reflecting continued strong demand and pipeline progress.

Eli Lilly has appointed Carolyn R. Bertozzi, a Stanford University professor and Howard Hughes Medical Institute Investigator, to its Board of Directors, effective December 8, 2025. Dr. Bertozzi will serve on the Science and Technology Committee and the Ethics and Compliance Committee, bringing expertise in chemistry and systems biology, which could influence Lilly's strategic direction and innovation efforts.

Eli Lilly reported strong Q4 2025 financial results, with revenue increasing 43% to $19.3 billion driven by Mounjaro and Zepbound. The company also issued 2026 revenue guidance in the range of $80 billion to $83 billion and non-GAAP EPS guidance of $33.50 to $35.00, indicating continued growth expectations.

Eli Lilly's proxy statement highlights the submission of orforglipron, an oral GLP-1 therapy, for obesity treatment approval in the U.S. and Japan, and for obesity and type 2 diabetes in the EU. The company also announced a landmark agreement with the U.S. government to broaden access to obesity medicines, aiming to reduce out-of-pocket costs for millions of Americans.